| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and YMLDLQPET peptide]
Accession # P04439-1(HLA-A*02:01)&P61769(B2M)&YMLDLQPET peptide |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |
| Synonyms |
HPV16; E7; MHC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
